Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer

Cancer Prevention Research

Volumn 3, Issue 11, 2010, Pages 1427-1434

  Liby, Karen T ^a   Royce, Darlene B ^a   Risingsong, Renee ^a   Williams, Charlotte R ^a   Maitra, Anirban ^b   Hruban, Ralph H ^b   Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID ETHYLAMIDE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID METHYL ESTER; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; GEMCITABINE; I KAPPA B KINASE; INTERLEUKIN 6; STAT3 PROTEIN; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DIET; EXPERIMENTAL MODEL; GENE MUTATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; SURVIVAL RATE; SYMPTOMATOLOGY; TRANSGENIC ANIMAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; NICOTINIC ACIDS; OLEANOLIC ACID; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES;

EID: 78649248267     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0197     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
3. Doucas H, Garcea G, Neal CP, Manson MM, Berry DP. Chemoprevention of pancreatic cancer: a review of the molecular pathways involved, and evidence for the potential for chemoprevention. Pancreatology 2006;6:429-39. (Pubitemid 44624276)
4. Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 2007;224:326-36.
5. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
6. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
8. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. Pancreatology 2008;8:110-25.
9. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69.
10. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810.
11. Suh N, Wang Y, Honda T, et al. A novel synthetic oleanane triterpenoid, CDDO, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999;59:336-41.
12. Balasubramanian S, Chandraratna RA, Eckert RL. Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. Carcinogenesis 2004;25:1377-85. (Pubitemid 39162704)
13. Samudio I, Konopleva M, Hail N, Jr., et al. CDDO-Im directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 2005;280:36273-82.
14. Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005;5:514-29.
15. Zhang Z, Rigas B. NF-κB, inflammation and pancreatic carcinogenesis: NF-κB as a chemoprevention target. Int J Oncol 2006;29:185-92.
16. Algul H, Treiber M, Lesina M, Schmid RM. Mechanisms of disease: chronic inflammation and cancer in the pancreas-a potential role for pancreatic stellate cells? Nat Clin Pract Gastroenterol Hepatol 2007;4:454-62.
17. Sporn MB. Dichotomies in cancer research: some suggestions for a new synthesis. Nat Clin Pract Oncol 2006;3:364-73.
18. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
19. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
20. Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 2008;10:111-22.
21. Honda T, Rounds BV, Bore L, et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1999;9:3429-34.
22. Honda T, Honda Y, Favaloro FG, Jr., et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12:1027-30.
23. Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6:154-62.
24. Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995;38:3146-55.
25. Honda T, Janosik T, Honda Y, et al. Design, synthesis, and biological evaluation of biotin conjugates of CDDO for the isolation of the protein targets. J Med Chem 2004;47:4923-32.
26. Liby K, Risingsong R, Royce DB, et al. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res 2008;14:4556-63.
27. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72.
28. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:211-26.
29. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid CDDO-imidazole blocks nuclear factor-κB activation through direct inhibition of I-κB kinase β. Mol Cancer Ther 2006;5:3232-9.
30. Mihaljevic AL, Michalski CW, Friess H, Kleeff J. Molecular mechanism of pancreatic cancer-understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 2010;395:295-308.
31. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor--κ B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
32. Huang C, Yang G, Jiang T, Huang K, Cao J, Qiu Z. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010;29:51.
33. Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010;70:2445-54.
34. Harsha HC, Jimeno A, Molina H, et al. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 2008;7:4651-8.
35. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007;7:91-107.
36. Liby K, Risingsong R, Royce DB, et al. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res 2009;2:1050-8.
37. Liby K, Royce DB, Williams CR, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007;67:2414-9.
38. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
39. Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008;57:1420-30.
40. Funahashi H, Satake M, Dawson D, et al. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 2007;67:7068-71. (Pubitemid 47206534)
41. Fendrich V, Chen NM, Neef M, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010;59:630-7.
42. Mohammed A, Janakiram NB, Li Q, et al. EGFR inhibitor gefitinib prevents progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mice model. Cancer Prev Res 2010;3:1417-26.